iSERA Lifesciences is a listed company. Filings by its managers are published through SEBI (PIT + SAST). From 18 October 2025 to 18 October 2026, the disclosure feed for iSERA Lifesciences logged 31 filings by 31 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Across the 1,986 companies tracked on its exchange, the median is 4 filings; at 31 filings, this issuer sits above that mark.
Insider buying of iSERA Lifesciences has been absent for the past year. Most trades are made public on the day they happen. The shorter that gap, the sooner other investors can see what insiders have done.
Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
25 of 31 declarations
iSERA Lifesciences is a company specializing in the life sciences sector, listed on the XBOM. It focuses on developing innovative solutions to enhance human health.
Insider filings
Over the last 90 days, 31 filings published on 8 October 2026: 31 open-market purchases by insiders for €3.8M. Largest amounts: Shubhangi Dhanraj Garad (Promoter), purchases of €1.2M; Sumeet Dhanraj Garad (Promoter), purchases of €530k; Pratap Dadasaheb Deshmukh (Promoter), purchases of €349k.
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 14 October 2026 (UTC)